Structure via PubChem · Public domain (PubChem)
radium-223
Sign in to saveAlso known as Ra-223, 223Ra, radium ra-223, Radium Ra-223
Radium-223 (223Ra, Ra-223) is an alpha-emitting isotope of radium with half-life 11.435 days. It was discovered in 1905 by T. Godlewski, a Polish chemist from Kraków, and was historically known as actinium X (AcX). Radium-223 dichloride is an alpha particle-emitting radiotherapy drug that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover. The principal use of radium-223, as a radiopharmaceutical to treat metastatic cancers in bone, takes advantage of its chemical similarity to calcium, and the short range of the alpha radiation it emits.
In the Vinony graph
Within Vinony's link graph, radium-223 is referenced by 53 other articles, and connects out to alpha decay, monoclonal antibody and decay chain.
It sits within the topics Chemical pages without DrugBank identifier, Chemicals that do not have a ChemSpider ID assigned and Drugboxes which contain changes to verified fields.
Its subject is documented across 9 Wikipedia language editions.
Chemical data
- Formula
- Ra
- Molecular weight
- 223.0185 g/mol
- IUPAC name
- radium-223
- SMILES
- [223Ra]
- InChIKey
- HCWPIIXVSYCSAN-OIOBTWANSA-N
- Polar surface area
- 0 Ų
- H-bond donors
- 0
- H-bond acceptors
- 0
- Formal charge
- 0
via PubChem
Wikidata facts
- Instance of
- isotope of radium
- Subclass of
- radium
- Mass
- 223.019
- Image
- Radium-223.svg
Show 11 more facts
- spin quantum number
- 1.5
- atomic number
- 88
- neutron number
- 135
- decays to
- carbon-14
- half-life
- 11.43
- parity quantum number
- 1
- mass excess
- 17233.309
- binding energy
- 1713823.907
- canonical SMILES
- [Ra]
- chemical formula
- Ra
- isomeric SMILES
- [223Ra]
Sources (7)
via Wikidata · CC0
~6 min read
Encyclopedic overview
7 sectionsContents
- Origin and preparation
- Medical uses
- Mechanism of action
- Clinical trials and FDA and EMA approval
- Side effects
- Other radium-223-based compounds
- References
Radium-223 (223Ra, Ra-223) is an alpha-emitting isotope of radium with half-life 11.435 days. It was discovered in 1905 by T. Godlewski, a Polish chemist from Kraków, and was historically known as actinium X (AcX). Radium-223 dichloride is an alpha particle-emitting radiotherapy drug that mimics calcium and forms complexes with hydroxyapatite at areas of increased bone turnover. The principal use of radium-223, as a radiopharmaceutical to treat metastatic cancers in bone, takes advantage of its chemical similarity to calcium, and the short range of the alpha radiation it emits.
==Origin and preparation== Although radium-223 is naturally formed in trace amounts by the decay of uranium-235, it is generally made artificially, by exposing natural radium-226 to neutrons to produce radium-227, which decays with a 42-minute half-life to actinium-227. Actinium-227 (half-life 21.8 years) in turn decays via thorium-227 (half-life 18.7 days) to radium-223. This decay path makes it convenient to prepare radium-223 by "milking" it from an actinium-227 containing generator or "cow", similar to the moly cows widely used to prepare the medically important isotope technetium-99m.
Excerpted from Wikipedia’s “radium-223” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0